SecBot SecBot
PRESS-RELEASE ·Filed Aug 11, 2026

TOVX

Theriva Biologics, Inc.
NEUTRAL
Impact 5/10
Horizonmonths Processed3mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

The VIRAGE2 enrollment completion (H2 2026) and initial data (Q3 2027) are the next key catalysts, but the $11.3M cash runway into Q1 2027 creates financing overhang. Monitor for partnership, grant, or equity offering announcements given the 88% analyst bullish consensus but $11M market cap.

DirectionNeutral
Confidencemedium
Horizonmonths

VCN-01

▲ Bullish Named in this press release
Impact
Phase
Phase 2b completed; Phase 2a (VIRAGE2) authorized/enrolling; Phase 3 design aligned with FDA and EMA
Time to market
Likely 4-6 years if Phase 3 is successful, assuming the company secures funding/partnership to initiate a pivotal trial
Next catalyst
None dated

What to watchVCN-01 is the only meaningful asset at a ~$10M market-cap company. The positive VIRAGE Phase 2b data and FDA/EMA alignment on Phase 3 design are real positives, but the company has only ~$14M cash (runway into Q1 2027) and needs a partnership or dilutive financing to fund the pivotal trial. Watch for partnership/licensing announcements and VIRAGE2 interim data as the next catalysts, the stock is highly binary and prone to large swings.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.2300
T+0 close · Aug 11, 2026 · via day close
Latest settled
−18.09%
T+60 · $0.1884
Vs SPY
−17.95%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 11 $0.2300entry
  2. T+1 · 3mo ago +4.35%α +4.10% · $0.2400
  3. T+5 · 3mo ago −1.96%α −1.55% · $0.2255
  4. T+20 · 2mo ago +8.26%α +9.32% · $0.2490
  5. T+60 · 13d ago −18.09%α −17.95% · $0.1884
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Theriva Biologics reported Q2 2026 financial results with a net loss of $3.2M ($0.07 per share) vs $13.1M ($1.93 per share) in Q2 2025, driven by a $9.2M decrease in contingent consideration fair value adjustment. The company dosed first patients in the VIRAGE2 Phase 2a trial evaluating more frequent VCN-01 dosing in metastatic PDAC, but cash runway extends only into Q1 2027 with $11.3M on hand, raising financing risk for a clinical-stage company with no revenue.

Key Financial Metrics

EPS
−$0.07
Revenue
$0.00
est $0.00 · 0.0%
Rating
in line

Key Facts

  • First patients dosed in VIRAGE2 Phase 2a trial of VCN-01 in metastatic PDAC; enrollment expected to complete H2 2026 with data by Q3 2027
  • Cash and cash equivalents of $11.3M as of June 30, 2026; cash runway into Q1 2027
  • Net loss of $3.2M for Q2 2026 vs $13.1M in Q2 2025, primarily due to a $9.2M decrease in contingent consideration fair value adjustment
  • General and administrative expenses decreased 82% to $2.0M from $11.2M; R&D expenses decreased 35% to $1.3M from $2.0M
  • EPS of -$0.07 vs -$1.93 in prior year period, but weighted average shares increased from 6.8M to 45.9M
  • Proposed Phase 2/3 trial for VCN-01 in retinoblastoma; FDA discussion planned for Q3 2026
  • Phase 1 HNSCC results published in Clinical Cancer Research showing prolonged OS with VCN-01 + durvalumab

Financial Impact

Net loss of $3.2M in Q2 2026 vs $13.1M in Q2 2025; cash burn of $1.7M in H1 2026; $11.3M cash runway into Q1 2027

cashnet lossoperating expenses

Risk Factors

  • Cash runway only into Q1 2027 with no revenue; likely need to raise capital within 6-9 months
  • VIRAGE2 is a small 6-patient proof-of-concept trial; results may not support Phase 3 design
  • SYN-004 enrollment paused pending grant/partnership funding

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3342623

Track record

11 reports on TOVX

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +17.39% at T+60 after the Aug 4, 2026 report. 3 of 5 went positive at some point.

Filters
  1. Nov 12, 20264d ago Press Release Neutral 4/10 Entry $0.1600 to $0.1441 Now $0.1400 −12.50% ▼ −9.94% −9.57% vs SPY
  2. Nov 2, 202614d ago 8-K Neutral 5/10 Entry $0.1820 to $0.1900 Now $0.1400 −23.08% ▲ +4.40% +2.74% vs SPY
  3. Oct 20, 202627d ago DEF 14A Bearish 5/10 Entry $0.1966 to $0.1900 Now $0.1400 +28.79% ▲ +3.36% +2.18% vs SPY
  4. Aug 11, 202613w ago 8-K Neutral 4/10 No price data
  5. Aug 11, 202613w ago Press Release Neutral 5/10 Viewing Entry $0.2300 to $0.2400 Now $0.1400 −39.13% ▲ +4.35% +4.10% vs SPY
  6. Aug 4, 202614w ago 8-K Bearish 4/10 Entry $0.2300 to $0.2251 Now $0.1400 +39.13% ▲ +2.13% +1.93% vs SPY
  7. Jul 7, 202618w ago 8-K Bullish 5/10 Entry $0.2354 to $0.2378 Now $0.1400 −40.53% ▲ +1.02% +1.33% vs SPY
  8. Jun 11, 202622w ago Press Release Bullish 7/10 Entry $0.3070 to $0.3038 Now $0.1400 −54.40% ▼ −1.04% −1.58% vs SPY
  9. Apr 17, 202630w ago 8-K Bullish 7/10 Entry $0.4100 to $0.3400 Now $0.1400 −65.85% ▼ −17.07% −16.42% vs SPY
  10. Mar 12, 202635w ago 8-K Mixed 6/10 Entry $0.1800 to $0.1800 Now $0.1400 −22.22% · 0.00% +0.60% vs SPY
Showing 10 of 11

US Market Status

Market Closed · Opens in 6h 5m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 11, 2026